Original ArticleNon–Small Cell Lung CancerDefinition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
Keywords
Cited by (0)
Disclosure: Dr. Dingemans has received honoraria for serving on advisory board for BMS, MSD, Roche, Eli Lilly, Takeda, Pfizer, Boehringer Ingelheim (all to her institution) and has received a research grant from BMS (to her institution) outside the submitted work. Dr. Hendriks has received research funding from Roche and Boehringer Ingelheim (both to her institution); received honoraria for serving on advisory boards for Boehringer Ingelheim (to her institution) and BMS (to both her institution and herself); received travel reimbursement from Roche and BMS; participated in a mentorship program with key opinion leaders that was funded by AstraZeneca; and received personal fees for educational webinars from Quadia. Dr. Faivre-Finn has received research funds from AstraZeneca and Electra. Dr. Greillier has received grants, personal fees, and nonfinancial support from Roche, Novartis, AstraZeneca, Pfizer, Bristol-Myers Squibb, and MSD, as well as personal fees and nonfinancial support from Boehringer Ingelheim and AbbVie outside the submitted work. Dr. O’Brien has performed advisory work for the pharmaceutical companies Roche, BMS, Boehringer Ingelheim, MSD, Pierre Fabre, and AbbVie. Dr. Reck has received personal fees from AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, and Roche outside the submitted work. Dr. Lievens has received personal fees from AstraZeneca and RayStation outside the submitted work. Dr. Guckenberger has received grants and personal fees from AstraZeneca; grants from Boehringer Ingelheim and Elpen; grants from Novartis; and personal fees from BMS, MSD, and Chiesi outside the submitted work. Dr. Peled has received honoraria for serving as an advisor to AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, FoundationMedicine, Gaurdant360, MSD, Novartis, NovellusDx, Pfizer, Roche, and Takeda. Dr. Novello has received personal fees from AbbVie, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, MSD, Takeda, Roche, and Pfizer outside the submitted work. Dr. Scagliotti has received personal fees from Eli Lilly, AstraZeneca, Roche, Pfizer, and MSD outside the submitted work. Dr. Senan has received departmental research grants from ViewRay, Inc., Varian Medical Systems, and AstraZeneca and has received honoraria for serving on advisory boards for AstraZeneca, Celgene, Merck, and Eli Lilly. Dr. Paz-Ares has received personal fees from Roche, Lilly, MSD, BMS, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Amgem, Sanofi, Pharmamar, Merck, and Takeda outside the submitted work. Dr. Cufer reports consultant fees and honoraria from AstraZeneca, BMS, Boehringer Ingelheim, MSD, Pfizer, and Roche outside the submitted work. Dr. Infante reports personal fees from MSD and Astra Zeneca outside the submitted work. Dziadziuszko reports personal fees from AstraZeneca, BMS, Boehringer Ingelheim, MSD, and Pfizer and personal fees and reimbursement for travel expenses from Roche outside the submitted work. Dr. Peters reports rreceiving honoraria or consultation fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, F. Hoffmann-La Roche, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Novartis, Pfizer, Regeneron, Seattle Genetics, and Takeda; receiving honoraria for giving a talk at public events organized by AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Merck Sharp and Dohme, Novartis, and Pfizer; and receiving grants or research support as a (sub)investigator in trials sponsored by Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis, and Pfizer outside the submitted work. De. de Ruysscher reports receiving honoraria for serving on advisory boards of Bristol-Myers-Squibb, AstraZeneca, Roche/Genentech, Merck/Pfizer, and Celgene and receiving research grants from Bristol-Myers Squibb and Boehringer Ingelheim (all to his institution) outside the submitted work. Dr. Besse has received institutional grants for clinical and translational research from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work. The remaining authors declare no conflict of interest.